Terns Pharmaceuticals pulls in $87m Series C

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treating non-alcoholic steatohepatitis and other chronic liver diseases, has secured $87 million in Series C financing.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on treating non-alcoholic steatohepatitis and other chronic liver diseases, has secured $87 million in Series C financing. Deerfield Management Company led the round.

Source: Press Release